Select Page

Glumin XR 750mg sustained-release tablets

Ferron Par Pharmaceuticals

Product packaging may vary from one country to another.

Ingredients in every sustained-release tablet

Metformin HCL 750 mg

Each package contains

4 blisters of 15 sustained-release tablets

Other details

Dosage form:Tablet; coated; sustained-release
Flavour None

W.H.O. classification

ATC Level 1 A - Alimentary tract and metabolism
ATC Level 2 A10 - Drugs Used in Diabetes
ATC Level 3 A10B - Blood Glucose Lowering Drugs; excl. Insulins



NOT RECOMMENDEDThis item is not safe for use during pregnancy.


NOT RECOMMENDEDThis item is not safe for use during lactation.


NOT RECOMMENDEDThis item should not be used with alcohol.


CAUTIONThis item may not be safe for use while operating heavy machinery. Use with caution and after consultation with your doctor.

Available in


Dosage information

Metformin XR is not recommended for use in pediatric patients.

There is no fixed dosage regimen for the management of hyperglycemia in patients with type-2 diabetes with metformin XR or any other pharmacologic agent. Dosage of metformin XR must be individualized on the basis of both effectiveness and tolerance, while not exceeding the maximum recommended daily dose of 2000 mg for metformin XR.

Metformin XR should be started at a low dose, with gradual dose escalation, both to reduce gastrointestinal side effects and to permit identification of the minimum dose required for adequate glycemic control of the patient. During treatment initiation and dose titration (see Recommended dosing schedule), fasting plasma glucose should be used to determine the therapeutic response to metformin XR and identify the minimum effective dose for the patient. Thereafter, glycosylated hemoglobin should be measured at intervals of approximately 3 months. The therapeutic goal should be to decrease both fasting plasma glucose and glycosylated hemoglobin levels to normal or near normal by using the lowest effective dose of metformin XR, either when used as monotherapy or in combination with sulfonylurea or insulin.

Monitoring of blood glucose and glycosylated hemoglobin will also permit detection of primary failure, i.e., inadequate lowering of blood glucose at the maximum recommended dose of medication, and secondary failure, i.e., loss of an adequate blood glucose lowering response after an initial period of effectiveness. Short-term administration of metformin XR may be sufficient during periods of transient loss of control in patients usually well-controlled on diet alone.

The initial and maintenance dosing of metformin XR should be conservative in patients with advanced age, due to the potential for decreased renal function in this population. Any dosage adjustment should be based on a careful assessment of renal function. Generally, elderly, debilitated, and malnourished patients should not be titrated to the maximum dose of metformin XR. Monitoring of renal function is necessary to aid in prevention of lactic acidosis, particularly in the elderly.

Metformin XR is not recommended for use in pregnant women and pediatric patients.

Metformin XR should generally be given once daily with the evening meals. Patients should be informed that metformin XR must be swallowed whole and not crushed and chewed.


As mono– or combined therapy with sulphonylurea in patients with Non-insulin-dependent diabetes mellitus (type 2 diabetes) especially if overweight and whose blood glucose level cannot be controlled by diet alone.
As an adjuvant therapy in insulin-dependent diabetic patients with hardly controlled symptoms.